Novel Mechanisms and 'Complement-ary'Therapy in Periodontitis Project Summary Periodontal inflammation affects the majority of adults, while an estimated 10-15% develops severe periodontitis which exerts a systemic impact on the patients (e.g., increased risk for atherosclerosis and diabetes). However, the underlying immunopathology is poorly understood at the molecular level and effective, precisely targeted topical therapeutics are lacking. Clinical and histological observations, as well as experimental studies, suggest involvement of the complement system in periodontitis. However, the precise roles of the various complement pathways in periodontitis have not been defined. Consequently, it is currently uncertain which specific pathways or components need to be blocked to attenuate inflammatory pathology or, alternatively, maintained intact to support host defense. At a first stage, such mechanistic and interventional approaches necessitate the use of appropriate preclinical animal models. The overall objective of this proposal is to bridge the current mechanistic deficit of complement involvement in periodontitis to allow targeted intervention. The proposed project involves a consortium arrangement between the University of Louisville School of Dentistry and the University of Pennsylvania School of Medicine, and brings together leading, complementary, and integrated expertise in the areas of periodontal inflammation, microbial immune evasion, and complement-targeted therapeutics.
In Aim 1, a systematic approach is proposed to dissect the precise roles in periodontitis of individual pathways converging to or emanating from central complement hubs (C3, C5) that have already been implicated in preliminary studies.
In Aim 2, it is further proposed to investigate whether novel complement-dependent microbial evasion mechanisms, first identified by this group, promote both unwarranted inflammation and the cooperative survival of periodontal bacteria.
In Aim 3, those pathways or components that mediate destructive inflammation and/or pathogen persistence will be blocked, whereas those mediating host-protective effects will be kept intact. The experimental approach involves preclinical mouse models of inflammatory periodontitis and host-pathogen interactions. The mice to be used possess either intact complement system or carry specific mutations in key components that define major inductive or effector complement pathways. The translational approach involves the use of a panel of complement-specific therapeutic inhibitors. The availability of complement-specific drugs that have already undergone successful safety trials, indicates that promising interventions identified in this project have potential for rapid translation to clinical trials for periodontal disease treatment.
Novel Mechanisms and 'Complement-ary'Therapy in Periodontitis Project Narrative Conventional periodontal treatment is often not sufficient by itself to control destructive inflammation, which is mediated, in large part, through activities of the complement system. Our objective is to dissect mechanisms of complement involvement in periodontitis and accordingly apply appropriate complement-targeted drugs for treatment.
|Hajishengallis, George; Reis, Edimara S; Mastellos, Dimitrios C et al. (2017) Novel mechanisms and functions of complement. Nat Immunol 18:1288-1298|
|Olsen, Ingar; Lambris, John D; Hajishengallis, George (2017) Porphyromonas gingivalis disturbs host-commensal homeostasis by changing complement function. J Oral Microbiol 9:1340085|
|Hajishengallis, G; Krauss, J L; Jotwani, R et al. (2017) Differential capacity for complement receptor-mediated immune evasion by Porphyromonas gingivalis depending on the type of innate leukocyte. Mol Oral Microbiol 32:154-165|
|Hajishengallis, George; Korostoff, Jonathan M (2017) Revisiting the Page & Schroeder model: the good, the bad and the unknowns in the periodontal host response 40 years later. Periodontol 2000 75:116-151|
|Kajikawa, Tetsuhiro; Briones, Ruel A; Resuello, Ranillo R G et al. (2017) Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. Mol Ther Methods Clin Dev 6:207-215|
|Ricklin, Daniel; Reis, Edimara S; Lambris, John D (2016) Complement in disease: a defence system turning offensive. Nat Rev Nephrol 12:383-401|
|Maekawa, Tomoki; Briones, Ruel A; Resuello, Ranillo R G et al. (2016) Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3. J Clin Periodontol 43:238-49|
|Mastellos, D C; Ricklin, D; Hajishengallis, E et al. (2016) Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention. Mol Oral Microbiol 31:3-17|
|Hajishengallis, George; Moutsopoulos, Niki M; Hajishengallis, Evlambia et al. (2016) Immune and regulatory functions of neutrophils in inflammatory bone loss. Semin Immunol 28:146-58|
|Hajishengallis, George; Hajishengallis, Evlambia; Kajikawa, Tetsuhiro et al. (2016) Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. Semin Immunol 28:285-91|
Showing the most recent 10 out of 68 publications